trial

5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia

NCTId NCT02435654
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 128 (actual)
Sponsored by Kunming Medical University
Primary completion 2018-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
128 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2015-08
Primary completion
2018-12
Eligibility
ALL · 7 Years · 17 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Kunming Medical UniversityLead Sponsor
National Natural Science Foundation of ChinaCollaborator

Investigators

1
Xu xiufengPrincipal Investigator

Sites

1 total
Kunming, China

Facts & assertions

4 sourced
Enrollment
128
Phase
PHASE4
Primary Completion Date
2018-12
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Kunming Medical University
company
collaborator
National Natural Science Foundation of China
company
indication
Early-onset Schizophrenia
indication
investigator
Xu xiufeng
person